We conducted a KMSubtraction analysis of four large phase 3 RCTs that tested the addition of PD-1 inhibitors to chemotherapy programs in first-line advanced non-HER2-positive/HER2-negative advanced or metastatic GC or GEJC. This evidence concerns the gene ERBB2 and gastric cancer.